ASCO® 2023 Insights: "Phase III FIRE-4 Study - Influence of Baseline Liquid Biopsy Results in 1L Treatment Efficacy of FOLFIRI/Cetuximab in Pts With Tissue RAS-WT mCRC"
Comments 0
Login to view comments.
Click here to Login
